Нови Зеланд - Енглески - Ministry for Primary Industries

envirofume limited - aluminium phosphide - aluminium phosphide 570 g/kg - insecticide

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - estradiol hemihydrate, quantity: 1.033 mg (equivalent: estradiol, qty 1 mg); drospirenone, quantity: 2 mg - tablet, film coated - excipient ingredients: povidone; hypromellose; magnesium stearate; lactose monohydrate; purified talc; macrogol 6000; titanium dioxide; pregelatinised maize starch; maize starch; iron oxide red - hormone replacement therapy (hrt) for use in the short-term treatment in postmenopausal women with an intact uterus of the climacteric syndrome caused by deficient endogenous oestrogen production due to natural menopause, hypogonadism, castration or primary ovarian failure.

Ирска - Енглески - HPRA (Health Products Regulatory Authority)

pierre fabre medicament - aluminium hydroxide gel, dried magnesium carbonate light alginic acid silica colloidal hydrated - tablets chewable - 30/40/200/ milligram

Нови Зеланд - Енглески - Medsafe (Medicines Safety Authority)

johnson & johnson (new zealand) limited - aluminium hydroxide 80 mg/ml (added as aluminium / magnesium co-gel c655); magnesium hydroxide 80 mg/ml (added as aluminium / magnesium co-gel c655); simeticone 6 mg/ml (added as mg/ml of simethicone emulsion 30%) - oral suspension - active: aluminium hydroxide 80 mg/ml (added as aluminium / magnesium co-gel c655) magnesium hydroxide 80 mg/ml (added as aluminium / magnesium co-gel c655) simeticone 6 mg/ml (added as mg/ml of simethicone emulsion 30%) excipient: acesulfame potassium butyl hydroxybenzoate enhancer flavour fadp925 (natural sweetness) ethanol ethyl hydroxybenzoate mint flavour sn011397 propyl hydroxybenzoate purified water sorbitol xanthan gum xylitol

Нови Зеланд - Енглески - Medsafe (Medicines Safety Authority)

johnson & johnson (new zealand) limited - aluminium hydroxide 40 mg/ml (added as (10.85% aloh dried ) aluminium / magnesium co-gel c655, 9.4% overage); magnesium hydroxide 40 mg/ml (added as (10.85% mgoh) as aluminium / magnesium co-gel c655, 9.4% overage); simeticone 4 mg/ml (added as 13.3 mg/ml of simethicone emulsion 30%) - oral suspension - active: aluminium hydroxide 40 mg/ml (added as (10.85% aloh dried ) aluminium / magnesium co-gel c655, 9.4% overage) magnesium hydroxide 40 mg/ml (added as (10.85% mgoh) as aluminium / magnesium co-gel c655, 9.4% overage) simeticone 4 mg/ml (added as 13.3 mg/ml of simethicone emulsion 30%) excipient: acesulfame potassium butyl hydroxybenzoate enhancer flavour fadp925 (natural sweetness) ethanol ethyl hydroxybenzoate mint flavour sn011397 propyl hydroxybenzoate purified water sorbitol xanthan gum xylitol - relief from indigestion, heartburn, upset stomach, flatulence and wind pain.

Нови Зеланд - Енглески - Medsafe (Medicines Safety Authority)

johnson & johnson (new zealand) limited - aluminium hydroxide 40 mg/ml (added as (10.85% aloh dried ) aluminium / magnesium co-gel c655, 9.4% overage); magnesium hydroxide 40 mg/ml (added as (10.85% mgoh dried ) aluminium / magnesium co-gel c655 9.4% overage); simeticone 4 mg/ml (added as 13.3 mg/ml of simethicone emulsion 30%) - oral suspension - active: aluminium hydroxide 40 mg/ml (added as (10.85% aloh dried ) aluminium / magnesium co-gel c655, 9.4% overage) magnesium hydroxide 40 mg/ml (added as (10.85% mgoh dried ) aluminium / magnesium co-gel c655 9.4% overage) simeticone 4 mg/ml (added as 13.3 mg/ml of simethicone emulsion 30%) excipient: acesulfame potassium butyl hydroxybenzoate enhancer flavour fadp925 (natural sweetness) ethanol ethyl hydroxybenzoate mint flavour sn011397 propyl hydroxybenzoate purified water sorbitol xanthan gum xylitol - relief from indigestion, heartburn, upset stomach, flatulence and wind pain.

Малезија - Енглески - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

idaman pharma manufacturing sdn bhd - magnesium trisilicate; aluminium hydroxide -

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - emtricitabine, quantity: 200 mg; tenofovir disoproxil fumarate, quantity: 300 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; pregelatinised starch; croscarmellose sodium; magnesium stearate; lactose monohydrate; titanium dioxide; hypromellose; triacetin; indigo carmine aluminium lake - treatment of hiv-1 infection: cipla tenofovir + emtricitabine 300/200 is indicated for the treatment of hiv infected adults over the age of 18 years, in combination with other antiretroviral agents. pre-exposure prophylaxis: cipla tenofovir + emtricitabine 300/200 is indicated in combination with safer sex practices for pre-exposure prophylaxis (prep) to reduce the risk of sexually acquired hiv-1 in adults at high risk. this indication is based on clinical trials in men who have sex with men (msm) at high risk for hiv-1 infection and in heterosexual serodiscordant couples.

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - emtricitabine, quantity: 200 mg; tenofovir disoproxil succinate, quantity: 300.6 mg - tablet, film coated - excipient ingredients: macrogol 3350; indigo carmine aluminium lake; magnesium stearate; isopropyl alcohol; polyvinyl alcohol; microcrystalline cellulose; titanium dioxide; lactose monohydrate; purified talc; croscarmellose sodium; purified water; pregelatinised maize starch - treatment of hiv-1 infection,tenofovir/emtricitabine sandoz is indicated for the treatment of hiv infected adults over the age of 18 years, in combination with other antiretroviral agents.,pre-exposure prophylaxis,tenofovir/emtricitabine sandoz is indicated in combination with safer sex practices for pre-exposure prophylaxis (prep) to reduce the risk of sexually acquired hiv-1 in adults at high risk. this indication is based on clinical trials in men who have sex with men (msm) at high risk for hiv-1 infection and in heterosexual serodiscordant couples (see section 5.1 pharmacodynamic properties, clinical trials).

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - telmisartan, quantity: 40 mg; amlodipine besilate, quantity: 13.87 mg (equivalent: amlodipine, qty 10 mg) - tablet, multilayer - excipient ingredients: colloidal anhydrous silica; sodium hydroxide; sorbitol; magnesium stearate; pregelatinised maize starch; povidone; microcrystalline cellulose; maize starch; meglumine; colour - treatment of hypertension. treatment should not be initiated with this fixed-dose combination. (see dosage and administration)